4-year MonarchE results: increasing benefits with abemaciclib + ET for ER+/HER2- high-risk early BC скачать в хорошем качестве

4-year MonarchE results: increasing benefits with abemaciclib + ET for ER+/HER2- high-risk early BC

Patrick Neven, MD, Universitair Ziekenhuis Leuven, Leuven, Belgium, provides an overview of updated results of the Phase III monarchE (NCT03155997) trial investigating abemaciclib plus endocrine therapy for ER-positive, HER2-negative (ER+/HER2-), node-positive, high-risk early breast cancer. Previous results from the monarchE trial demonstrated a significant and clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS). 4-year follow-up results were presented at the San Antonio Breast Cancer Symposium (SABCS) 2022. At a median follow-up of 42 months, median IDFS was not reached in either group and the IDFS benefit previously reported was sustained. At 4 years, IDFS rates had improved from 79.4% to 85.8% (absolute difference 6.4%), and DRFS rates from 82.5% to 88.4% (absolute difference 5.9%). Overall, the results show an increasing benefit with abemaciclib plus endocrine therapy over endocrine therapy alone in the adjuvant setting for ER+/HER2- high-risk early breast cancer. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.